Affimed Reports 2023 Financial Results and Operational : vimarsana.com

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer...

Related Keywords

Germany , Russia , Ukraine , Texas , United States , Mannheim , Baden Wüberg , Andreas Harstrick , Artiva Allo , Alexander Fudukidis , University Of Texas Md Anderson Cancer Center , Genentech , International Accounting Standard Board , Program Updates , International Financial Reporting Standards , Safety Review Committee , Exchange Commission , Chief Medical Officer , Chief Executive Officer , Accepted Accounting , Cancer Center , Nasdaq Afmd , Ffimednv ,